ArticleActa crystallographica. Section F, Structural biology communications2016
Crystal structure of rofecoxib bound to human cyclooxygenase-2.
Article in Acta crystallographica. Section F, Structural biology communications, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 70 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
70 citing papers in PubMed, 177 citations in OpenAlex.
- Crosstalk through cholinergic and aryl hydrocarbon receptor pathways in the anti-inflammatory actions of microbial metabolites.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
- Design, synthesis, biological evaluation and computational studies of novel phthalimides as dual COX-2/5-LOX inhibitors.Molecular diversity · 2026Article
- Novel Pyrazole-4-Carbaldehyde Derivatives Having Potent COX-2 Inhibition and Anti-Tubercular Activity: Microwave-Assisted Green Synthesis and Molecular Docking.Journal of biochemical and molecular toxicology · 2026Article
- Article
- Unraveling the Anti-Arthritic Potential of Bioactive Compounds FromFood science & nutrition · 2026Article
- Exploring the Anti-Inflammatory Potential of Saudi Propolis Through Phytochemical Characterization, Molecular Docking, and Dynamic Simulation.Pharmaceutics · 2026Article
- Light-Promoted C-H/C-H Coupling of Imidazo[1,2-Molecules (Basel, Switzerland) · 2026Article
- In Vitro and In Silico Insights into the Antiproliferative Activity of Sesquiterpenes fromInternational journal of molecular sciences · 2026Article
- Antipyretic and Antinociceptive Activities of Tri-Phol-That Extract and Its Flavonoids:ACS omega · 2026Article
- Neuroprotective Effects of Tenoxicam and Phenethyl Isothiocyanate in an Aβ₁₋₄₂-Induced Rat Model of Alzheimer's Disease: Modulation of NF-κB/NLRP3 Signaling and Redox Homeostasis.Molecular neurobiology · 2026Article
- Structure-Activity Relationship of Flavonol O-Methylation Revealed by In Vitro, In Silico and Zebrafish Neurodegeneration Models.International journal of molecular sciences · 2026Article
- Integrative Network Pharmacology and Molecular Docking Analysis Uncovers Multi-Target Mechanisms of Alpha-Mangostin Against Acute Kidney Injury.Foods (Basel, Switzerland) · 2026Article
- Catalytic and structural comparisons of linoleate dioxygenases and their cytochrome P450 companions with enzymes of the cyclooxygenase cascade.The Journal of biological chemistry · 2026Review
- HPLC-ESI-QTOF-MS/MS-Guided Profiling of Bioactive Compounds in Fresh and Stored Saffron Corms Reveals Potent Anticancer Activity Against Colorectal Cancer.Pharmaceuticals (Basel, Switzerland) · 2026Article
- Integrated multi-omics elucidates the dual anti-inflammatory and neuroendocrine mechanisms of novel TCM plasters against primary dysmenorrhea.Frontiers in pain research (Lausanne, Switzerland) · 2026Article
- Computational and bioactivity investigations of flavonoid fraction from Dodonaea viscosa against oxidative stress and inflammation.Scientific reports · 2025Article
- Cycloartane-type saponins fromRSC advances · 2025Article
- Novel di-aryl chalcone derived pyrazole linked to methane sulfonyl pharmacophore as potent selective COX-2 inhibitors; design, synthesis, molecular modeling,Future medicinal chemistry · 2025Article
- Identification of Novel Bioactive Molecules in Black Chiloe's Giant Garlic (Antioxidants (Basel, Switzerland) · 2025Article
- Chemical Profiling and Assessment of Analgesic and Anti-Inflammatory Activity ofPharmaceuticals (Basel, Switzerland) · 2025Article
10 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Rofecoxib (Vioxx) was one of the first selective cyclooxygenase-2 (COX-2) inhibitors (coxibs) to be approved for use in humans. Within five years after its release to the public, Vioxx was withdrawn from the market owing to the adverse cardiovascular effects of the drug. Despite the widespread knowledge of the development and withdrawal of Vioxx, relatively little is known at the molecular level about how the inhibitor binds to COX-2. Vioxx is unique in that the inhibitor contains a methyl sulfone moiety in place of the sulfonamide moiety found in other coxibs such as celecoxib and valdecoxib. Here, new crystallization conditions were identified that allowed the structural determination of human COX-2 in complex with Vioxx and the structure was subsequently determined to 2.7 Å resolution. The crystal structure provides the first atomic level details of the binding of Vioxx to COX-2. As anticipated, Vioxx binds with its methyl sulfone moiety located in the side pocket of the cyclooxygenase channel, providing support for the isoform selectivity of this drug.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.